A blood test measuring folate receptor-positive circulating tumor cells (FR+CTCs) can predict which lung cancer patients will experience cancer progression after surgery, according to a 2026 study of 152 patients. Researchers found that patients with these cancer cells in their blood after surgery were 2.25 times more likely to develop cancer recurrence within three years. Gram Research analysis shows that patients whose blood test converted from negative before surgery to positive afterward faced the highest progression risk, suggesting this liquid biopsy could help doctors identify high-risk patients needing closer monitoring.
Researchers found that a simple blood test measuring special cancer cells called FR+CTCs could help doctors predict which lung cancer patients are at highest risk for cancer returning after surgery. In a study of 152 lung cancer patients who had surgery, those with these cancer cells in their blood after the operation were more than twice as likely to experience cancer progression within three years. According to Gram Research analysis, this blood test could help doctors identify patients who need closer monitoring or more aggressive treatment after surgery, potentially improving outcomes for people with non-small cell lung cancer.
Key Statistics
A 2026 study of 152 lung cancer patients found that those with FR+CTC cancer cells detected in blood after surgery had a 2.25 times higher risk of cancer progression within three years compared to those without these cells.
Among stage III lung cancer patients in the study, 69.39% had folate receptor-positive circulating tumor cells before surgery, compared to only 52.46% of stage I-II patients, suggesting disease severity correlates with these cancer cells in the bloodstream.
In the 152-patient study, patients whose blood test converted from negative before surgery to positive after surgery experienced the shortest time to cancer progression, indicating this conversion is a particularly strong warning sign for recurrence.
Stage III disease and postoperative FR+CTC positivity were identified as the only two independent predictors of 36-month cancer progression in the 152-patient cohort, with stage III conferring a 3.43 times higher risk.
The Quick Take
- What they studied: Whether a blood test that detects special cancer cells (FR+CTCs) can predict if lung cancer will come back after surgery
- Who participated: 152 lung cancer patients with stage I-IIIA non-small cell lung cancer who had surgery between 2018 and 2021. Blood samples were taken before and after surgery.
- Key finding: Patients who had these cancer cells in their blood after surgery were 2.25 times more likely to have cancer return within 3 years compared to those without these cells
- What it means for you: If you’ve had lung cancer surgery, this blood test could help your doctor know if you need extra monitoring or treatment. However, this is early research and should be discussed with your oncologist before making treatment decisions.
The Research Details
Researchers looked back at medical records of 171 lung cancer patients who had surgery to remove their tumors between 2018 and 2021. They collected blood samples from patients before surgery and after surgery, then tested these samples for special cancer cells called FR+CTCs (folate receptor-positive circulating tumor cells). These are cancer cells that escape into the bloodstream. The researchers followed patients for three years to see who developed cancer progression and compared this to whether they had these cells in their blood.
The study focused on stage I-IIIA non-small cell lung cancer, which is the most common type of lung cancer. By comparing blood test results to actual patient outcomes, the researchers could determine if the blood test was good at predicting who would have cancer return.
This approach is important because current methods of predicting cancer recurrence aren’t very reliable. A simple blood test that could identify high-risk patients would help doctors make better decisions about follow-up care and treatment intensity. This type of test is called a ’liquid biopsy’ because it uses blood instead of tissue biopsies, making it easier and less invasive to monitor patients over time.
This was a retrospective study, meaning researchers looked back at existing medical records rather than following patients forward in time. While this type of study can identify patterns, it’s not as strong as a prospective study where patients are followed from the start. The study included 152 patients with complete follow-up data, which is a reasonable sample size. The findings were statistically significant, meaning they’re unlikely to be due to chance. However, this research needs to be confirmed in larger, prospective studies before it becomes standard clinical practice.
What the Results Show
Among the 152 patients followed for three years, 36 developed cancer progression. The key finding was that patients with FR+CTC cancer cells detected in their blood after surgery had a 2.25 times higher risk of cancer returning compared to those without these cells. This was one of only two independent predictors of cancer progression identified in the study (the other being stage III disease, which had a 3.43 times higher risk).
Interestingly, the stage of cancer at diagnosis also mattered. Patients with stage III disease (more advanced cancer) had higher rates of these cancer cells in their blood before surgery (69.39%) compared to stage I-II patients (52.46%). After surgery, male patients, smokers, patients with squamous cell type lung cancer, and stage III patients all had higher rates of these cancer cells in their blood.
The most striking finding was that patients whose blood test converted from negative before surgery to positive after surgery had the worst outcomes and the shortest time before cancer progression. This suggests that the appearance of these cancer cells after surgery is a particularly strong warning sign.
The study found that several patient characteristics were associated with higher levels of FR+CTC cells in the blood after surgery, including male gender, smoking history, squamous cell histology (a specific type of lung cancer), and advanced stage disease. These associations suggest that certain patient groups may be at naturally higher risk and might benefit from more intensive monitoring.
Previous research has shown that circulating tumor cells in the blood can predict cancer outcomes, but most studies have looked at different types of cancer cells or used different detection methods. This study is notable because it specifically focuses on FR+CTC cells and their ability to predict progression after surgery in lung cancer. The findings align with the general principle that the presence of cancer cells in the bloodstream after surgery indicates incomplete treatment and higher recurrence risk.
This study has several important limitations. First, it’s a retrospective study looking back at past records rather than following patients forward, which can introduce bias. Second, the study only included 152 patients with complete data, which is relatively small for this type of research. Third, the study was conducted at a single institution, so results may not apply to all populations. Fourth, the blood test method (FR+CTC detection) is not yet standardized across hospitals, so results may vary depending on the testing technique used. Finally, this research needs to be validated in larger, prospective studies before it can be recommended for routine clinical use.
The Bottom Line
For lung cancer patients who have had surgery: Discuss with your oncologist whether FR+CTC blood testing might be appropriate for your situation. If available, this test could help identify if you’re at higher risk for cancer progression and may warrant closer monitoring or additional treatment. However, this is still research-level testing and not yet standard practice. Confidence level: Moderate - the findings are promising but need confirmation in larger studies.
This research is most relevant to: (1) Patients with stage I-IIIA non-small cell lung cancer who have had surgery, (2) Oncologists treating lung cancer patients, (3) Researchers developing new ways to predict cancer recurrence. This research does NOT apply to patients with other cancer types or those who haven’t had surgery.
If this blood test becomes available and is used after your surgery, results would typically be available within days to weeks. However, the real value comes from repeated testing over time - the study suggests that monitoring for conversion from negative to positive status is particularly important. Most cancer progression in this study occurred within the first three years after surgery.
Frequently Asked Questions
Can a blood test predict if my lung cancer will come back after surgery?
A new blood test measuring FR+CTC cancer cells shows promise in predicting lung cancer recurrence. A 2026 study found patients with these cells in their blood after surgery were 2.25 times more likely to experience progression within three years. Discuss with your oncologist if this test is available and appropriate for your situation.
What are circulating tumor cells and why do they matter?
Circulating tumor cells are cancer cells that escape into the bloodstream. Their presence after surgery suggests some cancer cells survived the operation. The study found that patients with folate receptor-positive versions of these cells had significantly worse outcomes, making them useful for identifying high-risk patients needing closer monitoring.
Is this blood test ready to use in my hospital?
This research is promising but still relatively new. The blood test for FR+CTC cells is not yet standard practice at most hospitals. Ask your oncology team whether they offer this testing or can refer you to a center that does. Larger studies are needed before it becomes routine care.
What should I do if my blood test shows these cancer cells after surgery?
If FR+CTC cells are detected in your blood after surgery, this suggests higher recurrence risk and warrants discussion with your oncologist about closer monitoring or additional treatment options. The study found that conversion from negative to positive status carries the highest risk, so regular follow-up testing may be recommended.
How often would I need this blood test if my doctor recommends it?
The study doesn’t specify exact testing intervals, but liquid biopsy tests are typically performed every 3-6 months during the first few years after surgery when recurrence risk is highest. Your oncologist would determine the appropriate schedule based on your individual risk factors and cancer stage.
Want to Apply This Research?
- If you have access to FR+CTC blood test results, track the test date, result (positive/negative), and any changes in results over time. Record these alongside your regular oncology appointments and imaging scans to see if patterns emerge.
- Set reminders for scheduled oncology follow-up appointments and blood work. If your doctor recommends FR+CTC monitoring, maintain consistent testing schedules (typically every 3-6 months) to catch any conversion from negative to positive status early.
- Create a timeline view showing your FR+CTC test results over time alongside other markers like imaging results and symptoms. This helps you and your doctor identify trends and make informed decisions about treatment intensity.
This research describes an investigational blood test that is not yet standard clinical practice. The findings are based on a single-center retrospective study and require validation in larger prospective studies before clinical implementation. This information is for educational purposes only and should not replace consultation with your oncologist. Do not make treatment decisions based solely on this research. Always discuss any new testing or treatment options with your healthcare provider who understands your complete medical history and current condition.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.